Trump Just Put Cannabinoids Back in the Spotlight — Science Might Finally Catch Up
This opinion piece was written by Calvin Rasode, Vice President, Marketing, Brains Bioceutical
When Donald Trump tweets, the world pays attention. Sometimes it is spectacle, sometimes it is strategy, but either way, the ripple effect is real.
On September 28, 2025, he posted a video on Truth Social about cannabinoids, framing them as a game-changer for health.
It was not a policy paper or a clinical trial announcement, but it did something arguably more powerful. It injected cannabinoids into the mainstream political conversation at a time when science is finally ready to deliver.
For decades, cannabinoids have carried baggage. To some, they are shorthand for counterculture, legalisation debates, and consumer wellness fads. To others, they represent a new class of therapeutic compounds capable of reshaping medicine. Both views contain a grain of truth, but the part that matters most is the science quietly advancing behind the headlines.
In laboratories and clinics across the world, cannabinoids are no longer being tested as lifestyle products. They are being studied as pharmaceutical ingredients held to the same standards as chemotherapy agents or antivirals.
In my own experience at Brains Bioceutical, I have seen how far this shift has gone. We are not talking about casual oils or gummies. We are talking about active pharmaceutical ingredients produced under ICH-Q7 standards, backed by drug master files, and used in clinical trials approved by regulators in the United States and Europe.
The progress is real. Cannabidiol (CBD) has already been approved in the U.S. and Europe for certain rare forms of childhood epilepsy. Clinical programs are expanding into multiple sclerosis, schizophrenia, and neurodegenerative diseases. Preclinical research is pointing to potential roles in sleep disorders, pain management, and even conditions like autism. Each of these steps is slow, methodical, and expensive — but they mark the difference between hype and medicine.
October 1, 2025
No Comments
October 1, 2025
No Comments
September 30, 2025
No Comments
That is why Trump’s September 28th video matters. Political attention can create momentum. It can pull cannabinoids out of regulatory limbo and force agencies, insurers, and policymakers to take them seriously.
This is not about celebrity endorsements or election theatrics. It is about creating the kind of environment where credible science can cross the finish line and reach patients who need new options.
The last cannabis boom was fueled by marketing promises and retail branding. The next one will be driven by data. Pharmaceutical cannabinoids are being produced with batch-to-batch consistency, tested for stability, and scrutinised by regulators. The companies working in this space are not chasing quick sales. They are building the foundation for drugs that could one day be prescribed as confidently as blood pressure pills.
Of course, the road ahead is not guaranteed. Cannabinoid research has to navigate complex regulations, shifting political winds, and the high cost of drug development. But the momentum is undeniable. With major pharmaceutical partners stepping in, with academic researchers publishing peer-reviewed studies, and with clinical data building year by year, cannabinoids are shedding their old reputation.
What Trump may have inadvertently done is give this progress a spotlight. By amplifying cannabinoids to a national audience on September 28, 2025, he shifted the conversation from niche medical journals to everyday discourse.
For patients, that could mean faster access to new therapies. For regulators, it could mean greater pressure to modernise outdated frameworks. And for companies producing APIs, it means the science they have been working on in relative obscurity is finally part of a bigger story.
The next decade could redefine cannabinoids. Not as cultural symbols, not as consumer supplements, but as pharmaceutical tools with the potential to reshape how we treat some of the most challenging conditions in modern medicine.
Trump’s video was not a clinical breakthrough. But it might have been the spark that pushes cannabinoids out of the shadows and into the centre of healthcare innovation.
The post Trump Just Put Cannabinoids Back in the Spotlight — Science Might Finally Catch Up appeared first on Business of Cannabis.
